Navigation Links
Biovail Concerned Shareholders Want Open Debate
Date:6/17/2008

Biovail CEO Refuses to Meet; Concerned Shareholders Believe It Reflects Unwillingness To Confront Issues and to Reveal His Inexperience and Lack of

Industry Knowledge

June 17 Conference Call with Analysts Available on BetterBiovail.com

All Shareholders Urged to See New Video and Vote Their YELLOW Proxy

TORONTO, June 17 /PRNewswire-FirstCall/ -- The Concerned Shareholders of Biovail Corporation (NYSE: BVF)(TSX: BVF) said today that a refusal by Biovail CEO William Wells to participate in a debate with Bruce Brydon, Concerned Shareholders' proposed CEO, sends a chilling message to Biovail shareholders.

"To make an informed vote, shareholders need a chance to evaluate each side," said a spokesman for The Concerned Shareholders. "Mr. Wells has limited experience in the pharmaceutical industry, and we believe his refusal to participate in a debate demonstrates is he is afraid to show -- one-on-one -- his lack of knowledge."

Mr. Wells's refusal to debate comes on the heels of an analysis by Glass Lewis & Co. that sharply criticizes the company and recommends a no-vote for all the company's nominees. The report also calls the appointment of Mr. Wells as CEO "inappropriate from a corporate governance standpoint" and suggests that there was an appearance of a conflict of interest in awarding lavish compensation packages to Mr. Wells and his predecessor at a time when the company is struggling financially.

"We believe Mr. Wells has limited knowledge of the industry and inadequate experience to run the company," the spokesman said. "But shareholders deserve to see his level of knowledge first hand -- face to face with Bruce Brydon, who has 30 years experience."

The Concerned Shareholders ask the incumbent Biovail Board and Mr. Wells to reconsider their stance and agree to the debate with Mr. Brydon.

"If they do not, we urge shareholders to take note of what this says," said the spokesman. "Do they want a Board and management team that is afraid to show shareholders what they know and what they don't know? Or do they want a Board and a leader who wants an open debate?"

All shareholders are urged to vote the YELLOW proxy in favour of the Concerned Shareholders slate of nominees. Copies of the proxy circular prepared by the Concerned Shareholders can be obtained via SEDAR (http://www.sedar.com) and http://www.betterbiovail.com or by contacting in Canada, Kingsdale Shareholder Services Inc. toll-free at 1-800-775-1986 or collect at 1-416-867-2272, or in the United States, Innisfree M&A Incorporated toll-free at 1-877-717-3929.

Certain statements contained in this release constitute forward-looking statements. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Concerned Shareholders, the Concerned Shareholders' nominees, the Company or its current or future management, are intended to identify forward-looking statements. Such statements reflect the Concerned Shareholders' or the Concerned Shareholders' nominees' current views with respect to future events and are subject to certain risks, uncertainties and assumptions. The Concerned Shareholders' nominees assume no responsibility for any such statements. Many factors could cause the company's actual results, performance or achievements that may be expressed or implied by such forward- looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include, but are not limited to, economic, business, technological, competitive and regulatory factors.


'/>"/>
SOURCE Bruce Brydon
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
2. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
3. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
4. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
5. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
6. Spherix Holds Annual Shareholders Meeting
7. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
8. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
9. Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
10. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
11. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... BILLERICA, Mass. , Nov. 30, 2016   ... announced that it has entered into a set of ... screening services for Merck,s collection of genetic reagents such ... libraries with Evotec,s screening expertise offers an accelerated pathway ... "Drug discovery starts with the identification of new targets, ...
Breaking Biology Technology:
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
Breaking Biology News(10 mins):